Aiming To Lead A Global Operation? Start In China!
Moving from China president to a CEO, from regional Asia head to a global pharmaceutical president, several recent senior executive appointments have people wondering if China is increasingly becoming the new launch pad for high flyers eyeing a global pharma leadership role.
You may also be interested in...
Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.
Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.